Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Stray Dog Capital is a venture capital firm that specializes in investments within the alternative protein sector, including plant-based, cultivated, and fermentation-derived food technologies. The firm aims to transform the global food system by supporting early-stage startups that provide sustainable and ethical alternatives to animal-based products. Their portfolio includes prominent names in the food biotechnology space, such as Beyond Meat, BlueNalu, and Upside Foods. By providing capital and strategic guidance, Stray Dog Capital plays a pivotal role in the growth of the cellular agriculture and synthetic biology industries. The firm typically participates in Seed and Series A funding rounds, focusing on companies that demonstrate high potential for scalability and impact. Based in Kansas, the team leverages deep expertise in food science and business operations to help their portfolio companies navigate the path to commercialization.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Stray Dog Capital.